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Lifestyle measures plus antihypertensive drug therapy 
should be used to treat adults with hypertension (1-4). 
Adults with clinical cardiovascular disease (coronary 
heart disease, heart failure, and stroke) should have 
their blood pressure reduced below 130/80 mmHg for 
secondary prevention of recurrent cardiovascular disease 
events (4). The blood pressure should be reduced below 
130/80 mmHg for primary prevention of cardiovascular 
disease in adults with an estimated 10-year risk of 
atherosclerotic cardiovascular disease ≥10% (4,5). The 
blood pressure should be reduced below 140/90 mmHg for 
primary prevention of cardiovascular disease in adults with 
an estimated 10-year risk of atherosclerotic cardiovascular 
disease less than 10% (4,5). Initiate antihypertensive drug 
treatment with 2 first-line drugs from different classes 
either as separate drugs or in a fixed-dose combination in 
adults with a blood pressure of ≥140/90 mmHg or with a 
blood pressure >20/10 mmHg above their blood pressure 
target (4).
The first antihypertensive drug administered to white 
and other non-black adults younger than 60 years of age 
with primary hypertension, should be an angiotensin-
converting enzyme (ACE) inhibitor or angiotensin receptor 
blocker (4,6). The second drug should be a thiazide 
diuretic (preferably chlorthalidone) or a calcium channel 
blocker. If a third antihypertensive drug is needed to 
control the hypertension, an ACE inhibitor or angiotensin 
receptor blocker plus a thiazide diuretic plus a calcium 
channel blocker should be administered (4,6). The first 
antihypertensive drug administered to white and other non-
black adults aged 60 years of age and older with primary 
hypertension should be a thiazide diuretic (preferably 
chlorthalidone) or a calcium channel blocker (4,6). If a third 
antihypertensive drug is needed to control the hypertension, 
a thiazide diuretic plus a calcium channel blocker plus an 
ACE inhibitor or angiotensin receptor blocker should 
be administered (4,6). The first antihypertensive drug 
administered to adult blacks with primary hypertension 
should be a thiazide diuretic (preferably chlorthalidone) or 
a calcium channel blocker (4,6). if a third antihypertensive 
drug is needed to control the hypertension, a thiazide 
diuretic plus a calcium channel blocker plus an ACE 
inhibitor or angiotensin receptor blocker should be 
administered (4,6).
Adults with hypertension and stable coronary heart 
disease should be treated with a beta blocker plus an ACE 
inhibitor or angiotensin receptor blocker (1,3,4,7-14). 
If a third antihypertensive drug is needed to control the 
hypertension, a beta blocker plus an ACE inhibitor or 
angiotensin receptor blocker plus a thiazide diuretic or 
a calcium channel blocker should be administered. If a 
fourth antihypertensive drug is required to adequately 
control the hypertension, an aldosterone antagonist should 
be administered (4). In persons with stable ischemic heart 
disease who have angina pectoris despite beta blocker 
treatment and persistent uncontrolled hypertension, 
a dihydropyridine calcium channel blocker should be 
added (1,3,4,7,8,15). The beta blockers that should be 
administered for treatment of hypertension in patients with 
coronary heart disease include carvedilol, metoprolol tartrate, 
metoprolol succinate, bisoprolol, nadolol, propranolol, and 
timolol (4). Atenolol should not be used (1,3,4,9,16,17). 
The nondihydropyridine calcium channel blockers 
verapamil and diltiazem are contraindicated if left 
ventricular systolic dysfunction is present (1,3,4). Carvedilol, 
metoprolol succinate, or bisoprolol are the beta blockers 
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If patients with an acute coronary syndrome have 
hypertension after therapy with a beta blocker plus an 
ACE inhibitor or angiotensin receptor blocker, a long-
acting dihydropyridine calcium channel blocker such as 
amlodipine or felodipine should be added to the therapeutic 
regimen (1,3).  Aldosterone antagonists should be 
administered to patients treated with beta blockers plus ACE 
inhibitors or angiotensin receptor blockers after myocardial 
infarction with left ventricular systolic dysfunction and heart 
failure or diabetes mellitus if their serum potassium is below 
5.0 meq/L and if their serum creatinine is ≤2.5 mg/dL in 
men and ≤2.0 mg/dL in women (1,3,4,18).
Patients with hypertension and heart failure with a 
decreased left ventricular ejection fraction should be treated 
with carvedilol, metoprolol succinate, or bisoprolol plus an 
ACE inhibitor or angiotensin receptor blocker or preferably 
an angiotensin receptor-neprilysin inhibitor plus a diuretic 
and if needed with an aldosterone antagonist (1,3,4,9,18,19). 
Nondihydropyridine calcium channel blockers are 
contraindicated in persons with heart failure and a reduced 
left ventricular ejection fraction (1,3,4,19,20).
Patients with hypertension and heart failure with a 
preserved left ventricular ejection fraction should have 
their volume overload managed with diuretics, their 
comorbidities treated, and their hypertension treated with a 
beta blocker plus an ACE inhibitor or angiotensin blocker 
plus an aldosterone antagonist (3,4,19,21,22).
Hypertensive adults with chronic kidney disease 
stage 3 or higher or stage 1 or 2 chronic kidney disease 
with albuminuria 300 mg and more per day should be 
administered an ACE inhibitor to slow progression of 
their chronic kidney disease (4,23-26). If an ACE inhibitor 
is not tolerated, these patients should be administered an 
angiotensin receptor blocker (4). Patients who have stage 
1 or 2 chronic kidney disease without albuminuria may be 
administered usual first-line antihypertensive drugs (4). If 
3 antihypertensive drugs are needed, these patients should 
be given an ACE inhibitor or angiotensin receptor blocker 
plus a thiazide diuretic plus a calcium channel blocker. After 
kidney transplantation, hypertension should be treated with 
a calcium channel blocker to improve glomerular filtration 
rate and kidney survival (4,27).
Hypertensive patients with a prior stroke or transient 
ischemic attack should be administered a thiazide diuretic 
or ACE inhibitor or angiotensin receptor blocker (4,28,29). 
If a third antihypertensive drug is needed, these patients 
should be given a thiazide diuretic plus an ACE inhibitor or 
angiotensin receptor blocker plus a calcium channel blocker.
Hypertensive pat ients  with peripheral  arter ia l 
disease should receive usual first-line antihypertensive 
drugs (4,30). There are no data showing that any one class of 
antihypertensive drugs is superior for treating hypertension 
in patients with peripheral arterial disease (4,30).
Thiazide diuretics, ACE inhibitors, angiotensin receptor 
blockers, and calcium channel blockers may be used as initial 
therapy in hypertensive diabetics (4,31-33). ACE inhibitors 
or angiotensin receptor blockers should be administered to 
hypertensive diabetics with persistent albuminuria (4,34). 
The ALLHAT study found that chlorthalidone was better 
than lisinopril, amlodipine, and doxazosin in reducing 
cardiovascular disease and renal outcomes in nondiabetics 
with hypertension and the metabolic syndrome (4,35). 
Beta blockers are the preferred antihypertensive drugs in 
hypertensive patients with a thoracic aortic aneurysm (4,36). 
Beta blockers also improve survival in patients with type 
A and with type B acute and chronic thoracic aortic 
dissection (4,37,38). If thoracic aorta dissection develops, 
beta blockers are the initial drug of choice for decreasing 
blood pressure, ventricular rate, dP/dt, and stress on the 
aorta (36,39).  Systolic blood pressure should be reduced 
to 100 to 120 mmHg and the ventricular rate decreased to 
lower than 60 beats/minute by intravenous propranolol, 
metoprolol, labetalol, or esmolol (36).
Pregnant women with hypertension should not be 
administered an ACE inhibitor, angiotensin receptor 
blocker, direct renin inhibitor, or atenolol because these 
drugs are fetotoxic (4,40,41). Pregnant women with 
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